Press Releases

GlobeNewswire, Inc.

Board of Directors Declared Total Dividends of $0.50 per Share for Third Quarter 2026 Base Dividend of $0.43 and Supplemental Dividend of $0.07 Per Share EVANSTON, Ill., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Fidus Investment Corporation (NASDAQ:FDUS)...

GlobeNewswire, Inc.

Steady revenue growth and adjusted EBITDA margin* expansion Three consecutive quarters of double-digit software Annual Recurring Revenue* (“ARR”) growth TORONTO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Altus Group Limited (ʺAltus Group”, “Altus” or “the...

GlobeNewswire, Inc.

Record Second-Quarter Net Revenue Growth of 36% to $6 million; Core Programmatic Revenue Grew by 27% Year Over Year SOUTH ORANGE, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing...

GlobeNewswire, Inc.

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway.

GlobeNewswire, Inc.

DULUTH, Ga., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Fox Factory Holding Corp. (NASDAQ: FOXF) (“FOX” or the “Company”), a premium brand and a global leader in the design, engineering and manufacturing of performance-defining products and systems for...

GlobeNewswire, Inc.

First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual amylin and calcitonin receptor...

GlobeNewswire, Inc.

Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss improving 26% from prior-year period Increasing...

GlobeNewswire, Inc.

Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical...

GlobeNewswire, Inc.

Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis (MS) relapses following positive FDA pre-IND...

GlobeNewswire, Inc.

NDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue to enroll Three Phase 3 studies of azetukalner in neuropsychiatry continue to advance, with...

GlobeNewswire, Inc.

Second quarter revenue of $1.1 billion, up 5% year-over-year and when adjusted for foreign exchange* Cloud Infrastructure Services revenue of $99 million, up 39% year-over-year and when adjusted for foreign exchange* Security revenue of $604...

GlobeNewswire, Inc.

PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in the second half of 2027 Presented...

GlobeNewswire, Inc.

MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with...

GlobeNewswire, Inc.

Announced Proposed Merger with Avere Therapeutics Preserving Capital in Support of Merger Closing; Continuing Clinical Transition and Legacy Asset Activities BELTSVILLE, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a...

GlobeNewswire, Inc.

Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of 2027 Cash, cash equivalents,...

GlobeNewswire, Inc.

Revenue of $64.1 million increased 7.6% compared to the prior year period Secured four new share-of-wallet wins, including a significant share-of-wallet win with a large national automotive parts retailer Productivity initiatives drove an 11%...

GlobeNewswire, Inc.

Generated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-year Raising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of 76% to...

GlobeNewswire, Inc.

Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) with topline results anticipated in early Q1 2027 TX45 APEX Phase 2...

GlobeNewswire, Inc.

$37 Million of TPOXX Sales Generated in the Second Quarter Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company,...

GlobeNewswire, Inc.

MYQORZO® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 MYQORZO Launched in Germany,...